Monte Rosa Therapeutics, Inc.·4

Mar 4, 4:50 PM ET

Warmuth Markus 4

4 · Monte Rosa Therapeutics, Inc. · Filed Mar 4, 2026

Insider Transaction Report

Form 4
Period: 2026-03-02
Warmuth Markus
DirectorPresident & CEO
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-03-02$17.92/sh5,466$97,974613,471 total
Footnotes (2)
  • [F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Markus Warmuth|2026-03-04

Documents

1 file
  • 4
    ownership.xmlPrimary

    4